Results 151 to 160 of about 2,763 (183)
Some of the next articles are maybe not open access.
Erenumab for episodic migraine prophylaxis
Expert Review of Neurotherapeutics, 2019Introduction: This paper reviews placebo-controlled randomized double-blind studies with erenumab for the prevention of migraine. Erenumab is a fully human monoclonal antibody (mAb), which specifically blocks the calcitonin gene-related peptide (GGRP) receptor.
Lucas Hendrik, Overeem +2 more
openaire +2 more sources
Improvement of Prurigo Nodularis With Erenumab
JAMA DermatologyThis case report describes a patient in her 50s with prurigo nodularis and itch at the elbows, which spread to all extremities, the trunk, and genital area.
Manuel P, Pereira, Martin, Metz
openaire +2 more sources
Erenumab: First Global Approval
Drugs, 2018Amgen and Novartis are developing erenumab (AIMOVIG™, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine. CGRP is a vasodilatory neuropeptide implicated in the pathophysiology of migraine and treatment with erenumab was associated with significant reductions in ...
openaire +2 more sources
Erenumab efficacy in migraine headache prophylaxis: A systematic review
International Immunopharmacology, 2023Mona Sadeghalvad +2 more
exaly